Atiquzzaman Mohammad, Er Lee, Djurdjev Ognjenka, Bevilacqua Micheli, Elliott Mark, Birks Peter C, Wong Michelle M Y, Yi Tae Won, Singh Anurag, Tangri Navdeep, Levin Adeera
BC Renal, Vancouver, British Columbia, Canada.
Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
Kidney Int Rep. 2024 Jan 27;9(4):830-842. doi: 10.1016/j.ekir.2024.01.039. eCollection 2024 Apr.
We investigated the implications of implementing race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation among real-world patients with chronic kidney disease (CKD) from British Columbia (BC), Canada.
This study included nondialysis-dependent patients with CKD aged ≥19 years who were registered in the Patient Records and Outcome Management Information System (PROMIS) as of March 31, 2016 (index date) with ≥1 serum creatinine measurement within 1 year before the index date. Patients with a history of kidney transplantation before the index date were excluded. CKD-EPI 2021 versus 2009 equation was the exposure variable. Difference in mean estimated glomerular filtration rate (eGFR) and number (%) of patients reclassified to a different eGFR category were estimated. We used Fine and Gray subdistribution hazard model to investigate the association between change in eGFR category and progression to kidney failure (incident maintenance dialysis or kidney transplantation) within 2 years.
A total of 11,604 patients (median age 73 years, 52% male) were included. Compared to the 2009 equation, eGFR from 2021 equation was on average 2.7 ml/min per 1.73 m higher. Variation was higher among males. Overall, ∼17% of the study sample were reclassified to a category with higher eGFR by 2021 equation (switchers). The highest proportion (28%) of patients were reclassified from G5 to G4. The risk of progressing to kidney failure was 22% less among switchers compared to nonswitchers; adjusted subdistribution hazard ratio (HR) (95% confidence interval [CI]) is 0.78 (0.65, 0.94).
CKD-EPI 2021 equation appeared to provide higher eGFR compared to 2009 equation. This higher eGFR values appeared to be concordant with subsequent real-world CKD progression outcomes. Higher eGFR from the 2021 equation may have substantial clinical implications in both diagnosis as well as long-term care of patients with CKD.
我们研究了在加拿大不列颠哥伦比亚省(BC)的现实世界慢性肾脏病(CKD)患者中应用无种族差异的慢性肾脏病流行病学协作组(CKD-EPI)2021方程的影响。
本研究纳入了年龄≥19岁、非透析依赖的CKD患者,这些患者截至2016年3月31日(索引日期)已登记在患者记录与结局管理信息系统(PROMIS)中,且在索引日期前1年内有≥1次血清肌酐测量值。排除索引日期前有肾移植史的患者。CKD-EPI 2021方程与2009方程为暴露变量。估计平均估计肾小球滤过率(eGFR)的差异以及重新分类到不同eGFR类别的患者数量(%)。我们使用Fine和Gray亚分布风险模型来研究eGFR类别变化与2年内进展至肾衰竭(开始维持性透析或肾移植)之间的关联。
共纳入11,604例患者(中位年龄73岁,52%为男性)。与2009方程相比,2021方程得出的eGFR平均每1.73平方米高2.7毫升/分钟。男性中的差异更大。总体而言,约17%的研究样本根据2021方程被重新分类到eGFR更高的类别(转换者)。比例最高(28%)的患者从G5重新分类到G4。与非转换者相比,转换者进展至肾衰竭的风险低22%;调整后的亚分布风险比(HR)(95%置信区间[CI])为0.78(0.65,0.94)。
与2009方程相比,CKD-EPI 2021方程似乎得出更高的eGFR。这种更高的eGFR值似乎与随后现实世界中的CKD进展结局一致。2021方程得出的更高eGFR可能对CKD患者的诊断和长期护理都具有重要的临床意义。